- Market Capitalization, $K 186,562
- Shares Outstanding, K 84,037
- Annual Sales, $ 36,140 K
- Annual Income, $ -71,450 K
- 60-Month Beta 2.02
- Price/Sales 27.48
- Price/Cash Flow N/A
- Price/Book 6.71
|Period||Period Low||Period High||Performance|
| || |
-0.47 (-17.47%)since 02/03/21
| || |
+0.89 (+66.92%)since 12/03/20
| || |
-2.62 (-54.13%)since 03/03/20
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMC, NOK, CRBP, GME, and MVIS.
Inside the top performing stocks in the top ETF of January.
After an unsuccessful clinical trial result sent shares of Corbus Pharmaceuticals Holdings (CRBP) plummeting in September, is now the time to buy? Corbus Pharmaceuticals Holdings Inc. ( CRBP )...
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today...
, /PRNewswire/ -- One under-the-radar company looks to be an absolute game-changer for the healthcare industry. That's because, despite "Big Pharma's" massive resources and staggering amounts of spending,...
One under-the-radar company looks to be an absolute game-changer for the healthcare industry. That’s ...
Corbus Pharmaceuticals (CRBP) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Investors need to pay close attention to Corbus Pharmaceuticals (CRBP) stock based on the movements in the options market lately.
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NK, RP, AJRD, AIM, and CRBP.